Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | AHR | P35869 | 3/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27244495 | 1.00 | TTR (0.54) | TTRCA1CA2AHRCYP11B1 | |
| SCHEMBL11728871 | 0.83 | TTR (0.71) | TTRCA1CA2AHRCYP11B1 | |
| SCHEMBL29465920 | 0.83 | TTR (0.71) | TTRCA1CA2AHRCYP11B1 | |
| SCHEMBL27244494 | 0.81 | CYP11B1 (0.43) | CYP11B1CYP11B2PDE5AMCHR1 | |
| SCHEMBL29908963 | 0.81 | CYP11B1 (0.43) | CYP11B1CYP11B2PDE5AMCHR1 | |
| SCHEMBL12608762 | 0.81 | MAOA (0.60) | TTR | |
| SCHEMBL20317304 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL20317265 | 0.76 | MEN1 (0.44) | — | |
| SCHEMBL237891 | 0.75 | AHR (0.79) | TTRCA1CA2AHR | |
| SCHEMBL20317232 | 0.74 | TTR (0.56) | TTRCA1CA2AHRCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022177280-A1 | COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISEASES COMPRISING COMPOUND THAT INHIBITS MTOR SIGNALING PATHWAY AS ACTIVE INGREDIENT | 알리아드바이오파마 주식회사 | 2022-08-25 | — | — | WO | claimed |
| US-12605358-B2 | Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient | ALIAD BIOPHARMA (KR) | 2026-04-21 | — | — | US | disclosed |
| WO-2022177280-A1 | COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISEASES COMPRISING COMPOUND THAT INHIBITS MTOR SIGNALING PATHWAY AS ACTIVE INGREDIENT | 알리아드바이오파마 주식회사 | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605358-B2 | Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient | APP, BACE1, MTOR | TTR 2510/4885CA1 3788/4885CA2 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.